National systemic anti-cancer therapy (SACT) regimen-specific consent forms – Uptake and feedback survey
Session type: Proffered paper sessions
The UK Chemotherapy Board issued guidance on consent for SACT1 in July 2016. National regimen-specific consent forms were published on the Cancer Research UK website in July 2016, starting with breast cancer and a generic form; other forms continue to be published throughout 2017.
A survey was conducted to:
- evaluate uptake of the national forms in the UK
- identify challenges related to introducing the forms
- obtain feedback on the forms
- use feedback to inform future project developments
A survey was built using SurveyMonkey®, piloted and then emailed to lead chemotherapy clinicians within NHS hospitals/Trusts in the UK in January 2017. Results were analysed after two weeks.
- 87 responses were received from NHS hospitals/Trusts in the UK.
- 92% and 74% of all responders stated that they were aware of the national consent forms and guidance on consent for SACT respectively.
- Various methods were/are used to consent adult patients to treatment with SACT before and after the launch of the national forms.
- 30 hospitals/Trusts stated that they were using the national forms; 17 others confirmed plans for implementation.
- Several reasons were listed for not using the forms.
- 73% (22) of hospitals/Trusts using the forms stated they were preferred to the previous method; 60% (18) stated the forms were very easy or easy to use.
- Key themes identified from feedback and comments were: legal review of forms, form length, local processes for use, need for forms for all tumour groups, paediatric forms, and electronic versions.
The results give an indication of the awareness and uptake of the forms in the UK, the challenges and benefits of introducing forms at NHS hospitals/Trusts, and some areas to improve to increase uptake. The comments received were positive overall and included constructive feedback on the forms. Project developments have been informed by the results.